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†Division of Molecular Biology, Ruđer Bosǩovic ́ Institute, HR-10000 Zagreb, Croatia
‡Faculty of Chemistry and Chemical Technology, University of Ljubljana, Vecňa pot 113, SI-1000 Ljubljana, Slovenia
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ABSTRACT: A series of cationic chlorido arene-iridium(III)
and arene-osmium(II) complexes with bidentate pyridyl
functionalized mesoionic carbenes (MIC) of the 1,2,3-
triazol-5-ylidene type have been prepared. The variations in
the ligand structures include the position of the pyridyl
substituent relative to the triazolylidene ring (N-wingtip vs C-
wingtip), phenyl versus ethyl substituents, and incorporation
of several functional groups at the phenyl substituents. Five
complexes have been characterized by X-ray structural analysis. All complexes, including osmium(II) and ruthenium(II)
analogues having a pyrimidyl in place of the pyridyl group, have been studied for their cytotoxic activity on a human cervical
carcinoma HeLa cell line. Two of the compounds, Ir5 and Ir9, were the most cytotoxic with IC50 values of 7.33 μM and 2.01
μM, respectively. Examination of their cytotoxic eﬀect on diﬀerent cell lines revealed that they preferentially kill cancer over
normal cells. The Ir5 and Ir9 compounds arrested cells in G2 and induced a dose-dependent increase in SubG0/G1 cell
population. Apoptosis, as the primary mode of cell death, was conﬁrmed by Annexin V/PI staining, detection of cleaved PARP,
and caspases 3 and 7 activity upon treatment of HeLa cells with both compounds. The higher toxicity of Ir9 is probably due to
its increased accumulation in the cells compared to Ir5. The role of glutathione (GSH) in the protection of cells against Ir5 and
Ir9 cytotoxicity was conﬁrmed by pretreatment of cells either with buthionine sulfoximine (inhibitor of GSH synthesis) or N-
acetyl-cysteine (precursor in GSH synthesis).
■ INTRODUCTION
Cancer is one of the leading causes of death worldwide, treated
mostly by surgery, radiotherapy, and chemotherapy.1 Despite a
broad use of well-known metal-based anticancer drugs, such as
cisplatin and its derivatives, two main disadvantages of
chemotherapy remain a problem in successful treatment of a
variety of tumor types. Chemotherapeutics are largely
ineﬃcient against drug-resistant tumors and are followed by
severe side eﬀects including nephrotoxicity, hepatotoxicity,
ototoxicity, and cardiotoxicity.2 This urges a need for
investigation of new compounds that will be highly toxic
against tumor cells and nontoxic for the healthy cell
population.
Recently, organometallic compounds have gained interest as
anticancer agent candidates, owing to their increased structural
variety, diverse stereochemistry, and modular way of ligand
selection compared to organic molecules. Despite possessing a
carbon−metal bond, these compounds are often kinetically
stable, uncharged, and relatively lipophilic. Their metal atoms
can be in a low oxidation state, making them suitable for
application in medicinal chemistry.3
Mesoionic carbenes (MIC) of the 1,2,3-triazol-5-ylidene
type are currently highly popular ligands in organometallic
chemistry.4,5 Apart from the fact that their use as a ligand class
is barely 10 years old, an important reason for their popularity
is their modular synthesis by Click-reaction. Thus, introducing
additional heteroatom donors on such ligands and tuning of
the steric and electronic properties is often easier compared to
the most other classes of N-heterocyclic carbenes (NHC).
Hence, metal complexes of such ligands were successfully used
in a variety of homogeneous catalytic processes. Additionally,
metal complexes of these ligands have been successfully
investigated for their intriguing redox properties, such as
electrocatalysts, and for their photochemical properties. One
ﬁeld of research, where metal complexes of MICs are slowly
but surely displaying promise, is their potential use in
anticancer research.5,6 This is perhaps not that surprising
considering the potential that metal complexes of various other
NHC ligands have shown in medicinal chemistry. Recently, we
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have shown that 1,2,3-triazolium salts, precursor for the 1,2,3-
triazol-5-ylidene MIC ligands, also possess anticancer activity.7
In the past years, we have been involved in the synthesis of
pyridyl-substituted MIC ligands and their metal complexes,
which are potent catalysts for a variety of homogeneous
catalytic processes.8 An important discovery in terms of ligand
synthesis was the development of methodologies for selective
alkylation of pyridyl-triazoles.9 Herein, we report on the
synthesis of a series of Os(II) and Ir(III) complexes, as well as
one Ru(II) analogue with pyridyl-MICs. We present a
comprehensive study involving 12 Os(II), 8 Ir(III) complexes,
and 1 Ru(II) complex, along with their cytotoxic properties.
The eﬀects of introduced ligands and metal centers on
cytotoxic properties as well as their mechanisms of action in
cells are discussed.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. The ligand precursors,
triazolium salts, were synthesized following procedures that
were recently reported by us.9,10 The variations in ligand
precursor structures of L1−L12 include the position of the
pyridyl substituent (N vs C-wingtip of the triazolylidene ring),
phenyl versus ethyl substituents, and incorporation of several
functional groups on the phenyl substituents (Scheme 1).
Triazole rings in L1−L7 are characterized by the N1-pyridyl
substituent (N-wingtip), whereas those in L8−L12 have the
chelating pyridine at C5 (C-wingtip). Ligand precursors L1−
L12 were used for the synthesis of osmium(II) (Os1−Os12) and
iridium(III) half-sandwich complexes (Ir1−Ir9). Transmetala-
tion protocol8 with Ag2O turned out to be the route of choice
aﬀording the products from moderate 50% yields to higher.
Additionally, in the particular case of ligand precursor L13,
pyrimidyl was used as a heterocycle (N-wingtip) instead of
pyridyl to construct complexes Os12 and Ru1.
The complexes were characterized via 1H and 13C NMR
spectroscopy and mass spectrometry. The disappearance of the
signal corresponding to the triazolium C−H proton in the 1H
NMR spectrum of the complexes was already a ﬁrst indication
of the formation of the complexes. In the 13C NMR spectra,
the peak corresponding to the metal-bound MIC-C was
observed between 159.6 and 160.9 ppm for the Os(II)
complexes and between 156.3 and 158.4 ppm for the Ir(III)
complexes. Molecular peaks corresponding to the cations were
observed for all the complexes in their HRESI mass spectra.
Crystal Structures. We were successful in obtaining single
crystals of compounds Os8, Os11, Ir5, Ir6, and Ir7 that were
suitable for X-ray diﬀraction studies (Figure 1). The two
osmium complexes and Ir6 crystallized as dichloromethane
solvates. All the metal centers were coordinated in a piano-
stool type of coordination. The Cp* ligands were bound in an
η5 way to the Ir(III) centers, and the cymene ligands were
bound in an η6 fashion to the Os(II) centers. The three “legs”
Scheme 1. Synthesis of Os(II), Ir(III), and Ru(II) Complexes
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of the piano-stool are then made up of the pyridyl-N and MIC-
C of the chelating ligands and an additional chloride ligand. As
it has been observed earlier, the bond lengths inside the
triazolylidene rings point to a delocalized situation (Table 1).
The metal-C(MIC) and the metal-N(pyridine) distances are all
in the expected range.4c,e,f The aryl substituents on the
triazolylidene rings are twisted out of plane as seen from angles
close to 50° between the two rings (Table 1).
Eﬀect of the Complexes on Cell Viability. This work
was stimulated by recent reports on cytotoxic properties of the
ligand precursors, 1,2,3-triazolium salts,7 as well as organo-
metallic compounds of triazolylidene structure.5,6 Some
triazolium salts exhibited high cell-type dependent cytotoxicity
against diﬀerent tumor cells. Those did not bind double
stranded DNA, but induced formation of reactive oxygen
species, which further triggered cell death.7 An excellent
activity proﬁle against a range of cell lines has been shown for
half-sandwich Ru(II) and Os(II) organometallics having
triazolylidene as a monodentate MIC ligand.6a The structures
of the half-sandwich Os(II), Ir(III), and Ru(II) compounds
Os1−Os12, Ir1−Ir9, and Ru1 are distinctly diﬀerent from the
compounds mentioned above, possessing bidentate pyridyl-
triazolylidene ligand that chelates the metal in N(pyridine)
^C(MIC) mode. In Os12 and Ru1 the pyridyl dent is replaced
by pyrimidyl.
First, all the complexes were evaluated for their cytotoxicity
potential on human cervical carcinoma (HeLa) cells, the cell
model system that was previously identiﬁed as suitable for the
screening of new compounds.11,12 The results of the screening
are collected in Table 2.
Cytotoxicity of complexes Os1, Os3−Os5, Os7, Os8, Os11,
Ir1−Ir3, Ir8, and Ru1 could not be determined due to their
poor solubility. Compound Ir9 with IC50 of 2.01 μM was the
most toxic followed by Ir5 (IC50 of 7.33 μM). Both compounds
are Cp*−iridium complexes of very similar structure having
Figure 1. Ball and stick models of Os8, Os11, Ir5, Ir6, and Ir7. Hydrogen atoms, counterions, and solvent molecules are omitted for clarity. Selected
bond lengths and angles are reported in Table 1.
Table 1. Bond Lengths (Å), Angles, and Dihedral Angles
(deg)
atoms and
planes Os8 Os11 Ir5 Ir6 Ir7
Bond lengths
M1−Cl1 2.40(1) 2.401(2) 2.40(1) 2.40(1) 2.39(1)
M1−C1 2.02(1) 2.040(6) 2.03(1) 2.01(1) 2.01(1)
M1−N4 2.15(1) 2.124(4) 2.13(1) 2.12(1) 2.14(1)
C1−C2 1.38(2) 1.398(7) 1.39(1) 1.38(1) 1.34(1)
C2−C3 1.45(2) 1.430(8) 1.44(1) 1.44(1) 1.47(1)
C2−N1 1.36(2) 1.358(7) 1.35(1) 1.35(1) 1.36(1)
N1−N2 1.32(2) 1.323(6) 1.32(1) 1.31(1) 1.30(1)
N2−N3 1.33(1) 1.343(6) 1.36(1) 1.35(1) 1.34(1)
N3−C1 1.35(1) 1.353(7) 1.36(1) 1.36(1) 1.38(1)
N1−C16 1.45(2) 1.462(7) 1.47(1) 1.47(1) 1.47(1)
N3−C8 1.46(1) 1.465(7) 1.44(1) 1.44(1) 1.44(1)
C3−N4 1.38(2) 1.385(7) 1.38(1) 1.37(1) 1.36(1)
M1−
center




75.9(4) 76.4(2) 76.7(3) 76.3(2) 75.9(4)
C1−M1−
Cl1
85.9(3) 85.4(2) 88.2(2) 89.7(2) 87.9(3)
N4−M1−
Cl1
84.8(3) 84.6(1) 85.6(2) 87.4(2) 86.8(2)
N3−C1−
C2
102.9(1) 105.5(5) 102.3(6) 102.9(5) 102.0(8)
Dihedral angles
Tz−Py 5.9(4) 2.0(1) 7.4(2) 8.5(3) 10.2(3)
Tz−Ar 48.1(5) − 44.1(2) 53.0(3) 56.4(3)
Organometallics Article
DOI: 10.1021/acs.organomet.9b00327
Organometallics 2019, 38, 4082−4092
4084
the N-wingtip ligand series, while only diﬀering in the phenyl
moiety being unsubstituted in Ir5 and 2,6-diisopropyl
substituted in Ir9.
On the basis of the results from Table 2, compounds Ir5 and
Ir9 were selected for screening on tumor cells of diﬀerent
origins and one normal cell line. These included HeLa cells,
laryngeal carcinoma (HEp2) cells, large cell lung carcinoma
(H460) cells, colorectal carcinoma (HCT-116) cells, ovarian
cancer (MES-OV) cells, and normal primary keratinocytes.
The results collected in Table 3 demonstrate similar toxicity of
both compounds on all tested tumor cell lines independent
from their origin, with Ir9 being consistently more cytotoxic
than Ir5. One of the most important features of a compound to
be considered as potential anticancer agent is selectivity, i.e., as
high as possible cytotoxicity against tumor as compared to the
nontumor cells. It is noteworthy that all examined tumor cell
lines proved to be considerably more sensitive to both
compounds as compared to the normal cell line, normal
primary keratinocytes (Table 3). The therapeutic index was
not calculated since the IC50 doses of both compounds in
keratinocytes could not be determined.
Cell Cycle and Cell Death Analysis. To shed light into
the mode of action that underlies the antiproliferative or/and
toxic activity of Ir5 and Ir9, we ﬁrst investigated their eﬀect on
the cell cycle. The ﬂow cytometric analysis upon propidium
iodide staining of cells treated with diﬀerent concentrations of
Ir5 and Ir9 during 72 h (Figure 2A) or with 7 μM Ir5 and 2 μM
Ir9 during 24−72 h (Figure 2B) was performed. It seems that
both compounds tend to arrest cells in the G2 phase of the cell
cycle, and push the cells further into cell death. But, it is
interesting to notice that IC50 dose of Ir
5 induces accumulation
of cells in the S phase of cell cycle, which is not a case for IC50
of Ir9. The S phase arrest implies problems with DNA
replication that triggers a “checkpoint”a cascade of signaling
events that puts the phase on hold until the problem is
resolved. It seems that these cells are unable to progress
through S phase when the checkpoint is inhibited and often
enter directly into premature mitosis.13 Further investigation is
needed to understand why this eﬀect is seen only upon Ir5
treatment and not after the treatment with Ir9. The SubG0/G1
cell population, which is measured in cell cycles analysis as
well, is characterized with a lower amount of DNA. The cells
that entered apoptosis from the G2/M phase of the cell cycle
or have lost DNA for any other reason, e.g., death by some
other form of oncosis, will appear in the SubG0/G1 region.
The Ir5 and Ir9 induce dose- and time-dependent increase of
SubG0/G1 cell population (Figure 2A and 2B).
To shed more light on the type of cell death, HeLa cells
were treated with Ir5 (7 μM) or Ir9 (2 μM), following the
Annexin V-FITC and PI staining 24−72 h after. The analyzed
data shown in Figure 3A indicated that the majority of cells die
by apoptosis, which we further conﬁrmed by detection of
cleaved PARP, a well-accepted apoptotic marker,14 in the
treated cells. As shown in Figure 3B, the treatment of HeLa
cells with 7 μM of Ir9 induced cleavage of PARP already 24 h
after the treatment. Due to the lower toxicity, the cleaved
PARP was not detected upon cell treatment with the same
concentration of Ir5 (7 μM). However, when the equitoxic
doses of Ir5 (33 μM) and Ir9 (10 μM) were used the cleavage
of PARP was detected for both compounds after 72 h
treatment (Figure 3C). In addition, 72 h upon cell treatment
with 7 μM and 33 μM of Ir5, and 2 μM and 10 μM of Ir9, the
activity of executor caspases 3 and 7 was measured. The results
showed that both compounds activated caspases 3/7, although
the activation was more visible upon Ir5 treatment (Figure
3D). It is likely that Ir9 induces the activity of other caspases
such as caspase 1.15 The possible involvement of autophagy
and necroptosis as cell death models was checked by
pretreatment of cells with baﬁlomycin A (BAF A), a known
inhibitor of the late phase of autophagy,16 and with the
inhibitor of necroptosis, necrostatin-1 (Nec-1).17 Afterward,
the cells were treated with diﬀerent concentrations of either Ir5
or Ir9. Both inhibitors failed in protection of the cells from cell
death, indicating that neither autophagy nor necroptosis are
involved in cell death induced by Ir5 or Ir9 (Figure 3E).
One of the possibilities for higher toxicity of Ir9 compared to
Ir5 could be increased accumulation of Ir9 in the cells due to
the small structural diﬀerence. In order to test this hypothesis,
we treated HeLa cells with diﬀerent concentrations of both
compounds during 3 h and measured the accumulation of
iridium by high resolution inductively coupled plasma mass








Os6 24.42 ± 5.56
Os7 nd
Os8 nd
Os9 89.41 ± 13.80
Os10 100.88 ± 11.61
Os11 nd




Ir4 28.52 ± 8.56
Ir5 7.33 ± 0.28
Ir6 17.52 ± 0.64
Ir7 45.02 ± 3.07
Ir8 nd
Ir9 2.01 ± 0.28
Ru1 nd
and = not determined due to insuﬃcient solubility.
Table 3. Eﬀect of Ir5 and Ir9 on Viability of Diﬀerent Cell
Lines
cell linea Ir5 (IC50 (μM))
b Ir9 (IC50 (μM))
b
HeLa 7.33 ± 0.28 2.01 ± 0.28
HEp2 13.30 ± 1.20 4.66 ± 0.59
H460 6.00 ± 0.90 3.2 ± 0.89
HCT-116 6.50 ± 0.81 3.02 ± 0.17
MES-OV 7.6 ± 0.86 4.08 ± 0.5
keratinocytes <100 <100
aHeLa = cervical carcinoma cells; HEp2 = laryngeal carcinoma cells;
H460 = large cell lung carcinoma cells; HCT-116 = colorectal
carcinoma cells; MES-OV = ovarian cancer cells; Keratinocytes =
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spectrometry (HR ICPMS). The accumulation of both
compounds in the cells increased with the time, but the
content of iridium upon Ir9 was higher than the one measured
upon Ir5 treatment (Figure 4). The higher level of Ir9 in the
cell, compared to the level of Ir5, could be one of the reasons
for its greater toxicity.
The Role of Glutathione (GSH) in Cell Response to Ir5
and Ir9. The role of GSH as a cell defense mechanism is well
described in the literature.18,19 Previously, we described GSH
as an important factor in the protection of cell upon induction
of reactive oxygen species (ROS),20,21 and upon treatment
with newly synthesized12 or newly isolated compounds.22
Recently, we identiﬁed a triazolium salt of 4-(4-methoxy-
phenyl)-3-methyl-1-(2-picolyl)-1H-1,2,3-triazolium hexa-
ﬂuorophosphate(V) structure, which induced ROS and
showed that GSH is involved in reduction of ROS-induced
toxicity.7 Here we show that pretreatment of HeLa cells with
buthionine sulfoximine (BSO), a speciﬁc inhibitor of GSH
synthesis, decreased cell survival upon treatment with Ir5 and
Ir9 (Figure 5A). The data imply a role of GSH in cell defense
against damages induced by both investigated compounds. The
important role of GSH in cell-stress protection was further
conﬁrmed by pretreatment of cells with N-acetyl-cysteine
(NAC), a precursor of GSH synthesis. Increased GSH amount
in the cell protects it against either Ir5 or Ir9 toxicity (Figure
5B). The protection role of GSH is more expressed in HeLa
cells upon Ir9 treatment as compared to Ir5. In order to
investigate the possibility of ROS-induced toxicity by Ir5 and
Ir9, we stained cells upon treatment with ﬂuorescent dye 5-
(and-6)-chloromethyl-29,79-dichlorodihydroﬂuorescein diace-
tate, acetyl ester (CM-H2DCFDA). The data obtained indicate
that neither Ir5 nor Ir9 induce ROS (Figure 5C). This was
further conﬁrmed by pretreatment of cells with a well-accepted
ROS scavenger tempol, which did not change survival rate of
cells compared to the one treated only with compounds Ir5
and Ir9 (Figure 5D). It is known that GSH has a role in other
physiological processes such as nutrient metabolism, defense
by detoxiﬁcation, and regulation of cellular metabolic functions
ranging from gene expression, DNA, and protein synthesis to
signal transduction, cell proliferation, and apoptosis.23
Previously, we showed importance of GSH detoxiﬁcation
role in cell defense against toxicity of several compounds.24
Elucidating the mechanisms through which GSH is involved in
defense against chlorido arene-iridium(III) complexes with
bidentate pyridyl functionalized mesoionic carbenes (MIC) of
the 1,2,3-triazol-5-ylidene type will be interesting for future
investigation.
■ CONCLUSION
We have synthesized 12 osmium(II), 9 iridium(III), and 1
ruthenium(II) chloride arene organometallic compounds that
are additionally coordinated with bidentate pyridyl and
pyrimidyl functionalized mesoionic carbenes (MIC) of the
1,2,3-triazol-5-ylidene type. All new compounds have been
fully characterized by means of standard analytical and
spectroscopic techniques. For ﬁve of them we were able to
provide X-ray structural analysis. The complexes have been
tested for their anticancer activity, and it is noteworthy that
this is the ﬁrst report on biological activity of this type of
organometallic compounds. Ir5 and Ir9 displayed the highest
eﬀect on cell viability in HeLa cells. They had a similar eﬀect
on diﬀerent tumor cell lines, but they were more cytotoxic
against tumor cells than normal cells. Moreover, both
complexes induced programmed cell death. GSH plays an
important role as a protection mechanism in Ir5- and Ir9-
induced cell death. Organoiridium complexes seem very
interesting for further investigation as potential anticancer
agents due to their selective highly toxic eﬀect on diﬀerent
tumor cell types.
■ EXPERIMENTAL SECTION
Chemistry. The reagents and solvents were used as obtained from
the commercial sources (Sigma-Aldrich, Fluka, Alfa Aesar). Ag2O
25
triazolium salts L1−L13,10 complexes Os1−Os7,8b Os12,8d Ir1−Ir4,8b
Ir8,8c and Ru18d were prepared as described previously.
NMR spectra were measured with a Jeol ECS 400 spectrometer at
25 °C. Proton and carbon spectra were referenced to Si(CH3)4 as the
internal standard. Chemical shifts are given on the δ scale (ppm).
Figure 2. Eﬀects of Ir5 and Ir9 on cell cycle. HeLa cells were treated either with diﬀerent concentrations of Ir5 and Ir9 during 72 h (A) or with
equitoxic doses of Ir5 (7 μM) and Ir9 (2 μM) during 24−72 h (B). A cell cycle distribution was assessed as described in the Experimental Section.
Data of one from three independent experiments are presented.
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Figure 3. Impact of Ir5 and Ir9 on cell death. HeLa cells were treated with 7 μM Ir5 and 2 μM Ir9 during 24−72 h. The percent of live, early
apoptotic, and late apoptotic/necrotic cells are shown. The data of one from three independent experiments are presented. Heat shock was used to
adjust data analysis parameters (10 min, 56 °C) (A). HeLa cells were treated 24 h with equimolar concentration (7 μM) of Ir5 and Ir9 (B) and with
equitoxic concentrations, Ir5 (33 μM) and Ir9 (10 μM) during 72 h (C). Control cells were collected either at 24 (B) or 72 h (C) time points.
Precision Plus Protein All Blue Prestained Protein Standard (Bio-Rad, USA) is indicated in the ﬁgure. ERK1/2 (B) and ERK2 (C) were used as
loading controls. Data of one from three independent experiments are presented. HeLa cells were treated with Ir5 (7 μM and 33 μM) and Ir9 (2
μM and 10 μM). The activity of caspase 3/7 was measured after 72 h. The values are presented as fold of control. Signiﬁcance was determined
between control (nontreated) and Ir5, respectively, Ir9 treated cells (*P < 0.05; **P < 0.01; ***P < 0.001). The experiment was repeated at least
three times (D). HeLa cells were pretreated either with 0.5 and 1 nM BAF A or 12.5 and 25 μM Nec-1. Two hours later the cells were treated with
diﬀerent concentrations of Ir5 and Ir9. Cell survival was determined 72 h later by MTT assay. Each point represents mean ± SD of at least three
independent experiments. All data are expressed as the average percentage of survival values relative to the untreated control ± SD or samples
treated with inhibitors alone (E).
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Coupling constants (J) are given in Hertz. The multiplicities are
indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet),
sept (septet), and m (multiplet). An Agilent 6210 ESI-TOF
spectrometer and Agilent 6224 time-of-ﬂight (TOF) mass spec-
trometer equipped with a double orthogonal electrospray source at
atmospheric pressure ionization (ESI) coupled to an Agilent 1260
HLPC were used for recording HRMS spectra.
X-ray data were collected with a Bruker Smart AXS. Data were
collected at 140(2) K using graphite-monochromated Mo Kα
radiation (Kα = 0.71073 Å). The strategy for the data collection
was evaluated using the Smart software. The data were collected by
the standard “omega scan techniques” and were scaled and reduced
using Saint+ software. The structures were solved by direct methods
using SHELXS-97 and reﬁned by full matrix least-squares with
SHELXL-97, reﬁning on F2.26
General Procedure for the Preparation of Complexes Os8−
Os11 and Ir5−Ir7, Ir9. The corresponding ligand precursor (2 equiv,
0.2 mmol) was mixed with basic silver(I) oxide (7 equiv, 0.7 mmol,
163 mg) and potassium chloride (20 equiv, 2 mmol, 155 mg) and was
dissolved under nitrogen in dry acetonitrile (10 mL). The reaction
mixture was stirred under the exclusion of light for 2 days. Afterward,
the corresponding chloro-bridged metal dimer precursor (1 equiv, 0.1
mmol) was added and stirring was continued for additional 2−3 days.
The remaining silver(I) oxide and silver(I) chloride that formed were
ﬁltered oﬀ through a pad of Celite, and all volatiles were removed in
vacuo. The crude product was then dissolved in methanol (5 mL).
KPF6 (8 equiv, 0.8 mmol, 147 mg) was added, and the solution was
stirred for 20 min. Slow addition of water (80 mL) resulted in
precipitation of the desired complexes, which were collected by
ﬁltration and air-dried. If the precipitation from water was not
successful, the product was extracted with dichloromethane (3 × 20
mL). Combined organic layers were dried over NaSO4 and
concentrated to ca. 5 mL volume. The product was precipitated by
the addition of hexane (50 mL) and collected by ﬁltration. The
complexes were obtained in moderate yields of 53% and higher.
Osmium Complexes. Os8. From L8 (65 mg) and [Os(p-
Cym)Cl2]2 (79 mg). Green solid. Yield: 65% (0.13 mmol, 96.4
mg). 1H NMR (400 MHz, CD2Cl2) δ = 9.18 (td, J = 5.7, 0.7 Hz, 1H,
Py−H), 8.01 (td, J = 8.1, 0.7 Hz, 1H, Py−H), 7.96 (ddd, J = 8.1, 1.4,
0.6 Hz, 1H, Py−H), 7.86 (ddd, J = 5.5, 2.4, 1.1 Hz, 2H, Ar−H),
7.67−7.61 (m, 3H, Ar−H), 7.37 (ddd, 1H, Py−H), 5.40 (dd, J = 13.7,
5.8 Hz, 2H, Cym−CH), 5.23 (d, J = 5.6 Hz, 1H, Cym−CH), 4.84 (d,
J = 5.6 Hz, 1H, Cym−CH), 4.53 (s, 3H, N−CH3), 2.24 (sept, J = 6.9
Hz, 1H, CH(CH3)2), 2.08 (s, 3H, Cym−CH3), 0.86 (d, J = 6.9 Hz,
3H, CH(CH3)2), 0.84 (d, J = 6.9 Hz, 3H, CH(CH3)2).
13C NMR
(100 MHz, CD2Cl2) δ = 160.9 (Tz−C), 157.8; 148.6; 147.5, 139.7,
137.8, 131.4, 130.0, 126.3, 125.4, 121.2 (all Ar/Py−C), 99.1, 98.4,
81.9, 77.7, 77.6, 72.4 (all Cym−C), 39.2 (N−CH3), 31.4 (CH-
(CH3)2), 22.6 (CH(CH3)2), 21.7 (CH(CH3)2), 18.6 (Cym−CH3).
HRMS (ESI+) m/z calcd. for C24H26ClN4Os
+ [M]+ = 597.1461,
found 597.1464.
Os9. From L9 (71 mg) and [Os(p-Cym)Cl2]2 (79 mg). Gray-green
solid. Yield: 53% (0.106 mmol, 82 mg). 1H NMR (400 MHz,
CD2Cl2) δ = 9.17 (dt, J = 5.7, 1.1 Hz, 1H, Py−H), 8.03−7.98 (m, 1H,
Py−H), 7.94 (dt, J = 8.1, 1.1 Hz, 1H, Py−H), 7.77 (d, J = 9.0 Hz, 2H,
Ar−H), 7.36 (ddd, J = 7.4, 5.7, 1.5 Hz, 1H, Py−H), 7.09 (d, J = 9.0
Hz, 2H, Ar−H), 5.44 (dd, J = 5.8, 1.1 Hz, 1H, Cym−CH), 5.38 (d, J
= 5.9 Hz, 1H, Cym−CH), 5.28 (d, J = 5.9 Hz, 1H, Cym−CH), 4.86
(dd, J = 5.5, 1.1 Hz, 1H, Cym−CH), 4.51 (s, 3H, N−CH3), 3.87 (s,
3H, O−CH3), 2.24 (sept, J = 7.0 Hz, 1H, CH(CH3)2), 2.09 (s, 3H,
Cym−CH3), 0.86 (d, J = 6.9 Hz, 3H, CH(CH3)2), 0.85 (d, J = 6.9 Hz,
3H, 21.7 (CH(CH3)2).
13C NMR (100 MHz, CD2Cl2) δ = 160.9 (Ar-
C), 160.8 (Tz−C), 160.0, 157.0, 147.9, 147.5, 138.9, 129.7, 125.9,
125.4, 120.4, 114.9 (all Ar/Py−C), 98.2, 97.9, 81.0, 76.9, 76.8, 71.2
(all Cym−C), 55.1 (O−CH3), 38.3 (N−CH3), 30.6 (CH(CH3)2),
21.8 (CH(CH3)2), 21.0 (CH(CH3)2), 17.8, 13.06 (Cym−CH3).
HRMS (ESI+) m/z calcd. for C25H28ClN4OOs
+ [M]+ = 627.1566,
found 627.1576.
Os10. From L10 (78 mg) and [Os(p-Cym)Cl2]2 (79 mg). Yellow
solid. Yield: 61% (0.122 mmol, 98 mg). 1H NMR (400 MHz,
CD2Cl2) δ = 9.17 (d, J = 5.8, 1.0 Hz, 1H, Py−H), 8.11 (d, J = 8.8 Hz,
2H, Ar−H), 8.03 (dd, J = 7.9, 1.3 Hz, 1H, Py−H), 7.96 (d, J = 8.1 Hz,
1H, Py−H), 7.91 (d, J = 8.9 Hz, 2H, Ar−H), 7.38 (ddd, J = 7.3, 5.9,
1.4 Hz, 1H, Py−H), 5.43 (d, J = 5.9 Hz, 1H, Cym−CH), 5.39 (d, J =
5.8 Hz, 1H, Cym−CH), 5.32 (d, J = 5.9 Hz, 1H, Cym−CH), 4.89 (d,
J = 5.6 Hz, 1H, Cym−CH), 4.55 (s, 3H, N−CH3), 2.27 (sept, J = 6.9
Hz, 1H, CH(CH3)2), 2.09 (s, 3H, Cym−CH3), 0.88 (d, J = 6.9 Hz,
3H, CH(CH3)2), 0.87 (d, J = 6.9 Hz, 3H, CH(CH3)2).
13C NMR
(100 MHz, CD2Cl2) δ = 160.2 (Tz−C), 156.9, 147.7, 147.0, 140.0,
128.1, 126.5 (q, J = 4 Hz, Ar−C), 125.6, 125.4, 125.3, 120.6, (all Ar/
Py−C), 99.0, 97.5, 80.8, 77.1, 77.0, 72.0 (all Cym−C), 38.6 (N−
CH3), 30.6 (CH(CH3)2), 21.9 (CH(CH3)2), 20.9 (CH(CH3)2), 17.8
(Cym−CH3). HRMS (ESI+) m/z calcd. for C25H25ClF3N4Os+ [M]+
= 665.1335, found 665.1340.
Os11. From L11 (55 mg) and [Os(Cym)Cl2]2 (79 mg). Yellow
solid. Yield: 69% (0.137 mmol, 95 mg). 1H NMR (400 MHz,
CD2Cl2) δ = 9.23−9.17 (m, 1H, Py−H), 8.05−7.99 (m, 1H, Py−H),
7.94−7.88 (m, 1H, Py−H), 7.41−7.34 (m, 1H, Py−H), 5.95 (d, J =
5.6 Hz, 1H, Cym−CH), 5.85 (d, J = 6.1, 1H, Cym−CH), 5.78 (d, J =
5.8, 1H, Cym−CH), 5.49 (d, J = 5.8, 1H, Cym−CH), 4.78−4.57 (m,
2H, N−CH2CH3), 4.45 (s, 3H, N−CH3), 2.36 (sept, J = 6.9 Hz, 1H,
CH(CH3)2), 2.21 (s, 3H, Cym−CH3), 1.66 (t, J = 7.4 Hz, 3H, N−
CH2CH3), 0.98−0.90 (m, 6H, CH(CH3)2). 13C NMR (100 MHz,
CD2Cl2) δ = 159.6 (Tz-5C), 157.7, 151.8, 148.7, 147.2, 139.6, 126.0,
120.8 (all Ar/Py−C), 97.7, 96.9, 81.1, 79.3, 77.1, 72.0 (all Cym−C),
49.4 (N−CH2CH3), 38.9 (N−CH3), 31.5 (CH(CH3)2), 22.3
(CH(CH3)2), 18.6 (CH(CH3)2), 15.3 (N−CH2CH3). HRMS (ESI
+) m/z calcd. for C20H26ClN4Os
+ [M]+ = 549.1455, found 549.1453.
Iridium Complexes. Ir5. From L8 (65 mg) and [IrCp*Cl2]2 (80
mg). Bright-yellow solid. Yield: 63% (0.126 mmol, 93 mg). 1H NMR
(400 MHz, CD2Cl2) δ = 8.76 (dt, J = 5.7, 1.1 Hz, 1H, Py−H), 8.13−
8.06 (m, 2H, Py−H), 8.00−7.96 (m, 2H, Ar−H), 7.67−7.61 (m, 3H,
Ar−H), 7.50 (ddd, J = 6.8, 5.7, 2.2 Hz, 1H, Py−H), 4.61 (s, 3H, N−
CH3), 1.42 (s, 15H, Cp*−CH3). 13C NMR (100 MHz, CD2Cl2) δ =
156.5 (Tz−C), 153.7, 148.7, 148.5, 140.2, 138.0, 131.1, 130.0, 126.3,
125.3, 121.3 (all Ar/Py−C), 91.2 (Cp*−C), 39.3 (N−CH3), 8.7
(Cp*−CH3). HRMS (ESI+) m/z calcd. for C24H27ClIrN4+ [M]+ =
599.1553, found 599.1508.
Ir6. From L9 (71 mg) and [IrCp*Cl2]2 (80 mg). Bright-yellow
solid. Yield: 73% (0.143 mmol, 112 mg). 1H NMR (400 MHz,
CD2Cl2) δ = 8.76 (dd, J = 5.8, 0.5 Hz, 1H, Py−H), 8.08 (ddd, J = 7.9,
1.6, 0.3 Hz, 1H, Py−H), 8.01 (d, J = 8.1 Hz, 1H, Py−H), 7.88 (d, J =
8.9 Hz, 2H, Ar−H), 7.49 (ddd, J = 7.4, 5.9, 1.4 Hz, 1H, Py−H), 7.09
(d, J = 7.0 Hz, 2H, Ar−H), 4.57 (s, 3H, N−CH3), 3.88 (s, 3H, O−
CH3), 1.44 (s, 15H, Cp*−CH3). 13C NMR (100 MHz, CD2Cl2) δ =
161.6 (Ar−C), 156.3 (Tz−C), 153.8, 148.8, 148.2, 140.1, 131.0,
126.7, 126.3, 122.6, 121.0, 114.9 (all Ar/Py−C), 91.2 (Cp*−CH3),
55.9 (O−CH3), 39.1 (N−CH3), 8.8 (Cp*−CH3). HRMS (ESI+) m/z
calcd. for C25H29ClIrN4O
+ [M]+ = 629.1659, found 629.1616.
Ir7. From L10 (78 mg) and [IrCp*Cl2]2 (80 mg). Bright-yellow
solid. Yield: 75% (0.15 mmol, 122 mg). 1H NMR (400 MHz,
Figure 4. The accumulation of Ir5 and Ir9 in cells. HeLa cells were
treated with diﬀerent concentrations of Ir5 or Ir9 for 3 h. The cells
were collected, and the amount of iridium was measured by HR
ICPMS. The data of three independent experiments are presented.
Signiﬁcance was determined between control (nontreated) and Ir5,
respectively, Ir9 treated cells (***P < 0.001).
Organometallics Article
DOI: 10.1021/acs.organomet.9b00327
Organometallics 2019, 38, 4082−4092
4088
CD2Cl2) δ = 8.77 (ddd, J = 5.7, 1.5, 0.7 Hz, 1H, Py−H), 8.21 (d, J =
8.3 Hz, 2H, Ar−H), 8.10 (ddd, J = 8.0, 1.4, 0.3 Hz, 1H, Py−H), 8.04
(td, J = 8.1, 1.4 Hz, 1H, Py−H), 7.91 (d, J = 8.8 Hz, 2H, Ar−H), 7.51
(ddd, J = 6.0, 1.4, 0.3 Hz, 1H, Py−H), 4.61 (s, 3H, N−CH3), 1.43 (s,
15H, Cp*−CH3). 13C NMR (100 MHz, CD2Cl2) δ = 157.2 (Tz−C),
153.8, 148.8, 148.6, 140.7, 140.2 (all Ar/Py−C), 132.9 (q, J = 33 Hz,
Figure 5. The role of GSH level on cell survival upon treatment with Ir5 and Ir9. Eight hours after seeding cells were pretreated for 16 hours with
0.001 μg/mL BSO (A) or 24 h after the seeding with 5 mM of NAC for 2 h (B). Afterward diﬀerent concentrations of Ir5 or Ir9 were added. The
cell survival was determined 72 h later by MTT assay. Each point represents the mean ± SD of at least three independent experiments. All data are
expressed as the average percentage of survival values relative to an untreated control ± SD or samples treated with either BSO or NAC alone. The
signiﬁcance in diﬀerences is indicated (*P < 0.05; **P < 0.01; ***P < 0.001). Twenty-four hours after seeding the cells were treated with diﬀerent
concentrations of Ir5 or Ir9 during either 60 or 180 min. H2O2 treatment (0.01%, 30 min) was used as a positive control for formation of ROS (C).
Each point represents the mean ± SD of two independent measurements performed in quadruplicates. Twenty-four hours after seeding cells were
pretreated for 2 h with 20 μM tempol. Afterward diﬀerent concentrations of Ir5 or Ir9 were added. The cell survival was determined 72 h later by
MTT assay. (D) Each point represents the mean ± SD of at least three independent experiments. All data are expressed as the average percentage
of survival values relative to an untreated control ± SD or samples treated with tempol alone.
Organometallics Article
DOI: 10.1021/acs.organomet.9b00327
Organometallics 2019, 38, 4082−4092
4089
Ar−C), 127.2 (q, J = 4 Hz, Ar−C), 126.4, 126.1 (all Ar/Py−C), 123.5
(q, J = 273 Hz, CF3), 121.2 (Ar/Py−C), 91.4 (Cp*−C), 39.4 (N−
CH3), 8.7 (Cp*−CH3). HRMS (ESI+) m/z calcd. for
C25H26ClF3IrN4
+ [M]+ = 667.1427, found 667.1391.
Ir9. From L12 (82 mg) and [Ir(Cp*)Cl2]2 (80 mg). Yellow solid.
Yield: 75% (0.15 mmol, 124 mg). 1H NMR (400 MHz, CD2Cl2) δ =
8.79−8.71 (m, 1H, Py−H), 8.14−8.08 (m, 1H, Py−H), 8.08−8.04
(m, 1H, Py−H), 7.60 (t, J = 8.0 Hz, 1H, Ar−H), 7.55−7.52 (m, 1H,
Py−H), 7.44−7.39 (m, 2H, Ar−H), 4.61 (s, 3H, N−CH3), 3.17 (sept,
J = 6.8 Hz, 1H, CH(CH3)2), 2.35 (sept, J = 6.8 Hz, 1H, CH(CH3)2),
1.41 (s, 15H, Cp*−CH3), 1.34 (d, J = 6.8 Hz, 3H, CH(CH3)2), 1.27
(d, J = 6.8 Hz, 3H, CH(CH3)2), 1.19 (d, J = 6.8 Hz, 3H, CH(CH3)2),
0.78 (d, J = 6.8 Hz, 3H, CH(CH3)2).
13C NMR (100 MHz, CD2Cl2)
δ = 158.4 (Tz−C), 153.3, 149.6, 148.7, 146.8, 146.4, 139.9, 134.4,
132.1, 126.5, 124.6, 124.4, 121.2 (all Ar−C), 91.1 (Cp*−C), 39.4
(N−CH3), 29.0 (CH(CH3)2), 27.9 (CH(CH3)2), 27.0 (CH(CH3)2),
25.3 (CH(CH3)2), 21.7 (CH(CH3)2), 21.6 (CH(CH3)2), 8.8 (Cp*−
CH3). HRMS (ESI+) m/z calcd. for C30H39ClIrN4
+ [M]+ = 683.2492,
found 683.2464.
Biology. Cell Culture. Human cervical carcinoma HeLa and
laryngeal carcinoma HEp2 cells were obtained from cell culture bank
(GIBCO BRL-Invitrogen, USA). Large cell lung carcinoma H460 and
colorectal carcinoma HCT-116 cell lines were obtained from
American Type Culture Collection (ATCC, USA). Human ovarian
cancer cell line MES-OV was obtained from Prof. Sikic group
(Stanford University, USA). Normal human skin keratinocyte line was
obtained from the foreskin of healthy boys, aged 3−8 years. Foreskin
samples were noninﬂamed and the children were free of any therapy
at least 1 month before the surgery.27 The cells were obtained at the
Neurochemical Laboratory, Department of Chemistry and Biochem-
istry, School of Medicine, University of Zagreb. All cell lines were
grown as a monolayer culture in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Sigma-Aldrich, USA), supplemented with 10% fetal bovine
serum (FBS; Sigma-Aldrich) in a humidiﬁed atmosphere of 5% CO2
at 37 °C and were subcultured every 3−4 days.
Cytotoxicity Assay. Cytotoxic activity of organometallic complexes
was determined by MTT assay28 adjusted accordingly. In short, the
cells were seeded into 96-well tissue culture plates. The next day
diﬀerent concentrations of compounds were added to each well in
quadruplicate. Upon 72 h incubation at 37 °C, the medium was
aspirated and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) dye (Sigma-Aldrich) was added. Three hours
later, formazan crystals were dissolved in DMSO, the plates were
mechanically agitated for 5 min, and the optical density at 545 nm was
determined on a microtiter plate reader (Awareness Technology Inc.,
USA). The cytotoxicity was expressed either as IC20, IC50, or IC80
(survival rate 80, 50, and 20% compared to nontreated, control cells,
which survival was set at 100%).
Cell Cycle and Cell Death Analysis. HeLa cells were seeded into
tissue culture plates and treated with diﬀerent concentrations of
compounds for the indicated time. Thereafter, both adherent and
ﬂoating cells were collected, washed with PBS and ﬁxed overnight in
96% ethanol at −20 °C. Fixed cells were treated with RNase A (0.1
mg/mL, Sigma-Aldrich) for 30 min in water bath (37 °C) and
afterward stained with propidium iodide (50 μg/mL, Sigma-Aldrich)
for 30 min in the dark. The DNA content was analyzed on ﬂow
cytometer (FACS Calibur, Becton Dickinson, USA). Data were
analyzed for cell cycle distribution in FlowLogic software (Inivai
Technologies, Australia) using cell cycle speciﬁc gating protocol and
Watson pragmatic convolution.
In order to determine the type of cell death, HeLa cells were
treated with diﬀerent concentrations of investigated compounds. After
speciﬁc time, both adherent and ﬂoating cells were collected, washed
two times with PBS and stained with Annexin V and/or PI
(propidium iodide) according to the producer’s protocol (Thermo-
Fisher Scientiﬁc, USA). The DNA content and Annexin V
ﬂuorescence were analyzed by ﬂow cytometry (FACS Calibur, Becton
Dickinson). Data were analyzed with FlowLogic software (Inivai
Technologies, Australia) using speciﬁc gating protocol. After
determination of protein concentration by Bradford analysis,29 the
30 μg of whole cell proteins were loaded on SDS polyacrylamide gel.
Well accepted marker of apoptosis, cleaved PARP,14 was determined
by using speciﬁc anti-PARP antibody (Cell Signaling Technology,
USA). As internal loading controls ERK1/2 or ERK2 were used
(Santa Cruz Technology, USA). In addition, the activities of caspases
3 and 7 were determined. Cells were seeded into tissue culture plates
and after 1 day treated with diﬀerent concentrations of investigated
compounds. Upon 72 h incubation Caspase Glo 3/7 Mix (Promega,
USA) was added, and the producer’s protocol was followed.
Luminometric signal was read on Fluoroskan Ascent FL (Thermo
Fisher Scientiﬁc, USA) spectrometer. The possible role of autophagy
and necroptosis as cell death models was checked as previously
described.24
Accumulation of Iridium in the Cells. The total accumulation of
iridium was measured as described previously for measurement of
total cell platination21 with modiﬁcations. In short, upon treatment of
cells with diﬀerent concentrations of Ir5 or Ir9 during 3 h, the cells
were rinsed with ice-cold PBS and harvested into 10 mL of ice-cold
PBS using a rubber policeman. After centrifugation, the cells were
resuspended in PBS, an aliquot was used for determination of cell
number. and the rest was digested in 70% nitric acid. Cell lysates were
heated for 2 h at 75 °C, diluted in 5% nitric acid and assayed for
iridium content. The amount of iridium was measured by a validated
high-resolution inductively coupled plasma mass spectrometry (HR
ICPMS) using the Element 2 (Thermo Finnigan, Germany).
Calibration standards were prepared from single-element standard
diluted in hydrochloric acid and water (1000 μg/mL; Agilent, USA).
The Role of Glutathione in Cell Response to Ir5 and Ir9. The role
of glutathione (GSH) in cell response to Ir5 and Ir9 was investigated
by MTT assay by pretreatment of cells with speciﬁc inhibitor of GSH
synthesis, buthionine sulfoximine (BSO) or precursor in GSH
synthesis N-acetyl-cysteine (NAC). To examine the inﬂuence of
GSH depletion on response of HeLa cells to selected compounds, 8 h
after the seeding the cells were pretreated with 0.001 μg/mL of BSO.
Sixteen hours later the cells were treated with diﬀerent concentrations
of either Ir5 or Ir9, and the cytotoxicity eﬀect was determined 72 h
later. To determine the inﬂuence of increase of GSH synthesis on cells
response to selected compounds, 5 mM NAC was added 2 h before
treatment of cells with diﬀerent concentrations of either Ir5 or Ir9.
Generation of ROS was determined using the ﬂuorescent dye 5-(and-
6)-chloromethyl-29,79-dichlorodihydroﬂuorescein diacetate, acetyl
ester (CM-H2DCFDA) (Life Technologies, USA) according to the
previously described protocol.19 Possible role of ROS in induction of
cells death was additionally checked by 2 h pretreatment with 20 μM
tempol, well accepted antioxidant30 and then treated with diﬀerent
concentrations of either Ir5 or Ir9. The cytotoxicity eﬀect was
determined 72 h later by MTT assay.
Statistical Analysis. Data were analyzed by unpaired Student’s t
test and expressed as a mean ± standard error of the mean. Data were
considered signiﬁcant when P values were lower than 0.05, and in the
ﬁgures, these are designated as *P < 0.05, **P < 0.01, or ***P <
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Kocěvar, M.; Kosm̌rlj, J. A mesoionic bis(Py-tzNHC) palladium(II)
complex catalyses “green” Sonogashira reaction through an
unprecedented mechanism. Chem. Commun. 2016, 52, 1571−1574.
(9) Bolje, A.; Kosm̌rlj, J. A Selective Approach to Pyridine Appended
1,2,3-Triazolium Salts. Org. Lett. 2013, 15, 5084−5087.
(10) Bolje, A.; Urankar, D.; Kosm̌rlj, J. Synthesis and NMR Analysis
of 1,4-Disubstituted 1,2,3-Triazoles Tethered to Pyridine, Pyrimidine,
and Pyrazine Rings. Eur. J. Org. Chem. 2014, 2014, 8167−8181.
(11) Burja, B.; Cimbora-Zovko, T.; Tomic,́ S.; Jelusic,́ T.; Kocěvar,
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